GSK plc — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
11-K
13F-HR
20-F
20-F/A
25-NSE
3
3/A
4
4/A
424B2
424B3
5
6-K
6-K/A
8-A12B
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3/A
F-3ASR
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
POS AM
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G/A
SD
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008227 | Jul 21, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-008196 | Jul 18, 2025 | — |
| 6-K | BLENREP US ODAC OUTCOME | 0001654954-25-008187 | Jul 18, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008185 | Jul 18, 2025 | — |
| 6-K | GSKS SHINGRIX FULLY LIQUID FDA APPROVAL | 0001654954-25-008162 | Jul 17, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008156 | Jul 17, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008109 | Jul 16, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-008058 | Jul 15, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008044 | Jul 15, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-008018 | Jul 14, 2025 | — |
| 6-K | GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA | 0001654954-25-008006 | Jul 14, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008001 | Jul 14, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007952 | Jul 11, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007905 | Jul 10, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007862 | Jul 9, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007835 | Jul 8, 2025 | — |
| 6-K | GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD | 0001654954-25-007810 | Jul 7, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007798 | Jul 7, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007781 | Jul 7, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007712 | Jul 3, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007648 | Jul 2, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-007602 | Jul 1, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007554 | Jul 1, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007495 | Jun 30, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007457 | Jun 27, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007408 | Jun 26, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007374 | Jun 25, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-007336 | Jun 24, 2025 | — |
| 6-K | DIRECTOR DECLARATION | 0001654954-25-007326 | Jun 24, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007308 | Jun 24, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-007299 | Jun 23, 2025 | — |
| 6-K | LINERIXIBAT FILE ACCEPTED BY EMA | 0001654954-25-007275 | Jun 23, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007271 | Jun 23, 2025 | — |
| 6-K | AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK | 0001654954-25-007230 | Jun 20, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007222 | Jun 20, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007211 | Jun 20, 2025 | — |
| 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 0001999371-25-007999 | Jun 18, 2025 | Dec 31, 2024 |
| 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS | 0001999371-25-007998 | Jun 18, 2025 | Dec 31, 2024 |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007141 | Jun 18, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-007075 | Jun 17, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-006946 | Jun 16, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-006923 | Jun 13, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-006901 | Jun 13, 2025 | — |
| 6-K | GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA | 0001654954-25-006893 | Jun 13, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-006865 | Jun 12, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-006857 | Jun 12, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-006822 | Jun 11, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-006802 | Jun 11, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-006759 | Jun 10, 2025 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-006712 | Jun 9, 2025 | — |